Related Experiment Video
Updated: Oct 23, 2025

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
Published on: June 2, 2014
Raynaud's phenomenon secondary to erenumab in a patient with chronic migraine
Agaath Hedina Manickam1, Alina Buture2, Esther Tomkins3
1Department of Human Genetics and Molecular Biology Bharathiar University Coimbatore India.
Abstract:
Raynaud's phenomenon is a rare side effect of CGRP monoclonal antibodies. These molecular treatments are a relatively new class of drugs for the prevention of migraine. It is likely that we will see this side effect more often in the future. Patients with a background of Raynaud's phenomenon may experience worsening of their symptoms if started on these treatments.
Related Concept Videos
Disorders of the Autonomic Nervous System
Raynaud's disease, also known as Raynaud's...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

